Alice Schuch

Dr. Alice Schuch

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 October 2022 in Annals of Hepatology
Verified
Journal Article
Open access
LTLouise Torres
Louise Torres
ASAlice Schuch
Alice Schuch
LLLarisse Longo
Larisse Longo
BVBruna Bressan Valentini
Bruna Bressan Valentini
GGGABRIELA GALVAO
GABRIELA GALVAO
MAMario Reis Alvares-da-Silva
Mario Reis Alvares-da-Silva
Liver fibrosis is an important prognosis marker in non-alcoholic fatty liver disease (NAFLD). Biopsy has been considered the gold-standard method for measuring liver fibrosis; however, it is an invasive procedure. Non-invasive diagnostic tools have been developed, such as clinical scores and magnetic resonance elastography (MRE), which is the most accurate non-invasive method to determine liver fibrosis. Thus, the aim was to determine the NAFLD Fibrosis Score (NFS) and the Fibrosis-4 Score (FIB-4) cut-off points that best identify NAFLD patients at risk for developing liver fibrosis. Single-center cross-sectional study with prospective recruitment of NAFLD (training-cohort) and MAFLD (validation-cohort) patients undergoing MRE. The NFS and the FIB-4 cut-off points that best-differentiated patients with fibrosis, using the MRE as the standard method, were determined. Two cohorts were analyzed, a training cohort that included the initial 183 patients with NAFLD and a validation cohort that included 289 patients. In the training cohort, 60.1% had mild steatosis and 11.5% had liver fibrosis ≥ F1 by MRE. ROC curves were developed for FIB-4 and NFS, and the cut-off points chosen were 1.505 (sensitivity=85% and specificity=86%) for FIB-4 and -0.835 (sensitivity=100% and specificity=70%) for NFS, showing greater specificity than the cut-off points currently used (51% and 76%, respectively). The two cohorts exhibited similar characteristics and similar sensitivity and specificity results for the chosen cut-off points. This study has shown cut-off points with greater specificity and excellent sensitivity to guide the indication for further liver evaluation by MRE in NAFLD patients.

1 May 2022 in Radiologia Brasileira
Verified
Journal Article
Open access
NCNatália Henz Concatto
Natália Henz Concatto
SWStephanie Sander Westphalen
Stephanie Sander Westphalen
RVRubia Vanceta
Rubia Vanceta
ASAlice Schuch
Alice Schuch
GLGustavo Felipe Luersen
Gustavo Felipe Luersen
CGCaroline Lorenzoni Almeida Ghezzi
Caroline Lorenzoni Almeida Ghezzi
Resumo Acretismo placentário é uma condição caracterizada pela implantação anormal da placenta, que pode ser subdividida em três espectros de acordo com o seu grau de invasão: placenta acreta (ultrapassa a decídua basal e adere ao miométrio), placenta increta (penetra o miométrio) e placenta percreta (invasão da serosa uterina ou de tecidos/órgãos adjacentes). A incidência de acretismo placentário aumentou significativamente nas últimas décadas, principalmente em função da elevação das taxas de cesarianas, sendo este o seu principal fator de risco. A sua identificação pré-natal precisa permite um tratamento ideal com equipe multidisciplinar, minimizando significativamente a morbimortalidade materna. Os exames de escolha são a ultrassonografia e a ressonância magnética (RM), sendo a RM um método complementar indicado quando a avaliação ultrassonográfica é duvidosa, para pacientes com fatores de risco para acretismo placentário ou quando a placenta tem localização posterior. A RM é preferível também para avaliar invasão de órgãos adjacentes, oferecendo um campo de visão mais amplo, o que melhora o planejamento cirúrgico. Diversas características na RM são descritas no acretismo placentário, incluindo bandas hipointensas em T2 intraplacentárias, protuberância uterina anormal e heterogeneidade placentária. O conhecimento desses achados e a combinação de mais de um critério aumentam a confiabilidade do diagnóstico.

1 January 2024 in Revista da Associação Médica Brasileira
Verified
Journal Article
Open access
PDF file
PPPaulo Victor Alves Pinto
Paulo Victor Alves Pinto
FCFernando Morbeck Almeida Coelho
Fernando Morbeck Almeida Coelho
ASAlice Schuch
Alice Schuch
MZMauricio Zapparoli
Mauricio Zapparoli
RBRonaldo Hueb Baroni
Ronaldo Hueb Baroni
Renal cell carcinoma (RCC) is one of the most common cancers worldwide, with approximately 4,31,288 new cases and 1,79,368 deaths globally in 2020 and 81,800 new cases in the United States alone1 1 Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209-49. https://doi.org/10.3322/caac.21660 https://doi.org/10.3322/caac.21660... ,2 2 Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73(1):17-48. https://doi.org/10.3322/caac.21763 https://doi.org/10.3322/caac.21763... . RCC may present with flank pain, mass, or hematuria, but its incidence has increased due to incidental diagnosis through imaging methods3 3 Volpe A, Panzarella T, Rendon RA, Haider MA, Kondylis FI, Jewett MA. The natural history of incidentally detected small renal masses. Cancer. 2004;100(4):738-45. https://doi.org/10.1002/cncr.20025 https://doi.org/10.1002/cncr.20025... .

27 June 2025 in Abdominal Radiology
Verified
Journal Article
Closed access
PDF file
MFMarília da Cruz Fagundes
Marília da Cruz Fagundes
FCFernando Morbeck Almeida Coelho
Fernando Morbeck Almeida Coelho
GNGuilherme Gotti Naves
Guilherme Gotti Naves
GTGiovanna Sawaya Torre
Giovanna Sawaya Torre
MGMarcelo de Macêdo Gusmão
Marcelo de Macêdo Gusmão
RBRonaldo Hueb Baroni
Ronaldo Hueb Baroni

Verified
Journal Article
Open access
GCGabriela Carboni
Gabriela Carboni
LTLouise Torres
Louise Torres
GFGabriela Furlin
Gabriela Furlin
GMGabriela Sequeira de Campos Morais
Gabriela Sequeira de Campos Morais
RVRubia Vanceta
Rubia Vanceta
ASAlice Schuch
Alice Schuch
To evaluate the relationship between the magnetic resonance imaging-derived proton density fat fraction (MRI-PDFF) and liver size in patients with metabolic dysfunction-associated steatotic liver disease (MASLD), as well as to explore the role of determining the craniocaudal diameter of the right hepatic lobe (CCDHL), measured at the midclavicular line, and liver volumetry as complementary tools in the assessment of hepatic steatosis. This was a single-center, cross-sectional, prospective study including 289 patients with MASLD who underwent multiparametric MRI for the evaluation of hepatic steatosis, which was categorized by the MRI-PDFF value. Liver size measurements included the CCDHL, liver volume from automated segmentation, and its difference from the total expected liver volume (eLV), calculated with the Vauthey formula. A significant positive correlation was observed between the MRI-PDFF and liver size measurements, including the CCDHL (rs = 0.651; p < 0.001) and the eLV (rs = 0.568; p < 0.001). Patients with higher grades of steatosis showed a progressive increase in liver volume (p < 0.001). A receiver operating characteristic curve analysis demonstrated good diagnostic accuracy for the CCDHL and for the eLV in identifying moderate-to-severe steatosis (area under the curve: 0.76 and 0.83, respectively). The integrated assessment of the MRI-PDFF and liver size appears to be effective for the diagnosis, stratification, and monitoring of steatosis in patients with MASLD.

1 January 2024 in Radiologia Brasileira
Verified
Journal Article
Open access
PDF file
ASAlice Schuch
Alice Schuch
Prostate cancer is the second most common malignancy in men, second only to non-melanoma skin cancer(1 1 Gandaglia G, Abdollah F, Schiffmann J, et al. Distribution of metastatic sites in patients with prostate cancer: a population-based analysis. Prostate. 2014;74:210–6. ). The metastatic spread of prostate cancer occurs through local in-vasion, lymphatic dissemination, and hematogenous dissemi-nation, the most common sites being the pelvic lymph nodes and bones, where metastases are found in 99% and 84% of cases, respectively(2 2 Swanson GP, Hubbard JK. A better understanding of lymphatic drainage of the prostate with modern imaging and surgical techniques. Clin Genitourin Cancer. 2013;11:431–40. ). The question of inguinal lymph node in-volvement has emerged primarily due to the increased use of cross-sectional imaging methods such as CT and MRI, as well as metabolic evaluation by PET, especially with prostate-spe-cifc radiotracers such as PSMA. Metastases to inguinal lymph nodes are considered rare and present a diagnostic challenge because they are not typically included in conventional treat-ment felds such as radiotherapy or lymphadenectomy. The actual prevalence of and predictive factors for metastatic inguinal lymph nodes remain uncertain, and data in the litera-ture are based on imaging fndings without histopathological correlation(3 3 Jackson ASN, Sohaib SA, Staffurth JN, et al. Distribution of lymph nodes in men with prostatic adenocarcinoma and lymphadenopathy at presentation: a retrospective radiological review and implications for prostate and pelvis radiotherapy. Clin Oncol (R Coll Radiol). 2006;18:109–16. , 4 4 Schiller K, Stöhrer L, Düsberg M, et al. PSMA-PET/CT-based lymph node atlas for prostate cancer patients recurring after primary treatment: clinical implications for salvage radiation therapy. Eur Urol Oncol. 2021;4:73–83. ).